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Cytochrome c oxidase (CcO) is the fourth complex of the electron transport chain responsible for reducing molecular oxygen to water and coupling this reaction to proton pumping. 1, 2 CcO accepts electrons from cytochrome c and sequentially reduces its bimetallic copper A and heme a redox centers and finally reduces the binuclear active site composed of heme a 3 and copper B (Figure 1 ). Two conserved proton paths, the D-and K-paths, have been identified in bacterial and mammalian oxidases. The K-path takes up one to two protons during active site reduction, while the D-path takes up all other protons consumed during oxygen reduction or pumped across the membrane. [3] [4] [5] A bifurcated oxygen channel leading from the membrane environment to the binuclear active site has been crystallographically defined. 6, 7 A clear proton exit path has yet to be identified but may involve the heme propionate groups, propionate-associated water molecules, and/or a pair of arginines: Arg481 and Arg482 (Rhodobacter sphaeroides numbering is used unless otherwise noted.). [8] [9] [10] [11] [12] [13] CcO is thought to be a key regulator of oxidative phosphorylation rate and efficiency. [14] [15] [16] In eukaryotic systems, CcO activity is modulated by the presence of alternative isoforms of nuclearencoded accessory subunits, [17] [18] [19] [20] [21] [22] phosphorylation at as many as 14 residues including three residues on the conserved enzyme core, 23, 24 and binding of small molecules. [25] [26] [27] [28] [29] A crystallographicallydefined small molecule site with a bound bile acid ligand ( Figure 1 ) has been identified on both bacterial and mammalian CcO. This site is located in the membrane interface of subunits I and II, near the entrance to the K-path. 30, 31 It has been hypothesized to natively bind nucleotides based on shape, chemistry, and binding preference similarities between ADP and bile acids; 30 however, no structural evidence of nucleotide binding has been obtained.
R. sphaeroides CcO (RsCcO) has been established as a useful model system to investigate the activity and regulation of mammalian CcO. 32 It is suitable for characterizing the bile acid site, as both bovine and Rhodobacter oxidases bind bile acids in the same region involving homologous amino acid residues. 30, 31, 33 RsCcO and its K-path mutant form, E101A, are activated or inhibited by a diverse group of ligands that appear to bind at the bile acid site, including detergents, fatty acids, steroids, and porphyrins. 33, 34 RsCcO inhibition by these ligands and by mutations in the K-path has been attributed to an altered electron transfer equilibrium between heme a and a 3 cofactors. 33, [35] [36] [37] However, the native regulatory ligands for this conserved site remain elusive.
In order to understand the regulation of CcO at the bile acid site, a three-pronged computational approach was applied in this work to predict natural ligands with high complementarity to this conserved location. Initially, ligand comparisons were performed using the ROCS method [38] [39] to identify candidate molecules that are structurally and chemically similar to the crystallographically bound bile acid. Secondly, protein comparisons and alignments were performed using the SimSite3D method 40 to search for binding sites that have similar shape and chemistry to the RsCcO bile acid site. The native ligands bound to these similar sites were then investigated for their interaction with the bile acid site. Finally, high ranking ligand candidates from both the ROCS and SimSite3D approaches were docked using SLIDE [41] [42] to evaluate proteinligand interactions. All commercially available, soluble, high scoring candidate ligands were tested for their ability to alter the rate of RsCcO oxygen consumption. Of these ligand candidates, a cholesterol mimic, a thyroid hormone, retinoic acid, and select nucleotides inhibit RsCcO activity.
Ligand competition and mutational studies support the binding of these ligands to the bile acid site.
Our studies suggest that this region may be polyspecific for a number of native regulatory ligands that arrest CcO activity by stabilizing an oxidized binuclear center. This semi-oxidized state has some resemblance to the "resting" state of the bovine enzyme and may have a lesser tendency for oxygen radical byproduct formation.
Materials and Methods

Ligand database selection and processing
The were selected for testing based on TanimotoCombo score ranking, commercial availability, and ability to be solubilized at a concentration sufficient for assaying (≥ 100 µM).
Chemical and shape comparisons of the RsCcO bile acid site and diverse crystallographic sites
The second method used to assess candidate ligands, SimSite3D, is a protein binding site alignment and comparison tool that identifies a ranked list of sites most similar to the site of interest. Each site is represented using a set of pharmacophore points with associated bonding geometry and an accompanying solvent accessible molecular surface representing the detailed shape of the site. 40 The pharmacophore points denote positions where non-hydrogen atoms, of the appropriate chemistry, may be placed to form favorable polar or hydrophobic interactions with atoms in the protein. Polar pharmacophore points have an associated optimal hydrogen-bond direction, used to scale the energy estimate of the hydrogen bond according to its degree of linearity, while the molecular surface matching term ensures that highly ranked sites will have a shape very similar to that of the site of interest. 40 
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The RsCcO bile acid site was defined about the DOC crystallographic ligand (PDB: 3DTU). 31 The SimSite3D default protocol for template generation was used and included all pharmacophore points within 3.0 Å of at least one non-hydrogen atom of DOC. The molecular surface of the site, within 4.0 Å of DOC, was computed using the MSMS method. 45 Binding MOAD sites' pharmacophore points were optimally aligned to the pharmacophore points of the 
RsCcO purification and oxygen consumption activity assays
R. sphaeroides strains overexpressing the 37-2 wild-type (WT) CcO 46 and E101A mutant 47 were grown as previously described. Cell membranes were prepared and RsCcO was isolated by metal affinity chromatography as described for crystallographic studies. 47 Oxygen uptake rates
were measured with a Clark-type electrode, and turnover rates (TN in electrons per second per CcO molecule) were calculated as described in Hosler et al., 1992. 32 
Results
Chemical and geometric comparisons between the CcO crystallographic deoxycholate and diverse ligands
Mammalian and bacterial CcO proteins have been crystallized in the presence of bile acids, cholate in the case of bovine CcO (bovCcO) 30 and DOC in the case of RsCcO. 31 The ability of bile acids to bind to a conserved site and inhibit activity invokes the hypothesis that they mimic structurally similar, native regulatory molecules. In order to understand which potential physiological ligands are significantly similar to the bound DOC, the ROCS method was used to evaluate chemical and geometric similarities between DOC and ligands in the Binding MOAD database. Six chemical classes of ligands were identified, including bile acids, steroids, retinoic acid analogs, amino acid analogs, nucleotide and flavin analogs, and thyroid hormone analogs (Table 1 and Supplemental Table 1 ). ROCS alignments of these predicted ligands to the crystallographic DOC resulted in an overlay of polycyclic ligand groups with the DOC steroid ring system and aliphatic, carboxylate, or phosphorylated ligand tails with the DOC carboxylate tail ( Figure 2 and Supplemental Figure 1 ). It had been suggested previously that the bile acid site is in fact an allosteric regulatory site that binds ADP under physiological conditions. 30 The similarity between DOC and abundant adenine-containing ligands and nucleotides was also evaluated by ROCS with thirteen nucleotides, FAD, and a NAD + analog scoring highly structurally and chemically similar to DOC (Supplemental Table 2 ).
Chemical and geometric comparisons between the CcO bile acid site and diverse protein sites
In order to predict varied candidate ligands that complement RsCcO, rather than just those similar to DOC, the CcO bile acid binding site was compared to diverse ligand sites in Binding MOAD using the SimSite3D method. SimSite3D compares crystallographic protein sites based on surface chemistry and geometry, using no knowledge of the existing bound ligand or the underlying amino acid sequence. 40 This approach identified five classes of protein sites, characterized by their bound flavin, lipid, nicotinamide, nucleotide, and steroid ligands (Table 1 and Supplemental Table   3 ). Interestingly, no bile acid binding proteins were identified as high scoring by SimSite3D.
Striking overlap between the ROCS and SimSite3D ligand candidates is observed as both methods identified hydrocortisone, cholesterol, aldosterone, FAD, NAD + , GDP, ATP, and ADP, despite ROCS only using DOC ligand information and SimSite3D only using knowledge of the RsCcO bile acid site with DOC removed.
Prediction of critical amino acid residues and candidate ligand binding orientations in the CcO bile acid site
The ROCS method of ligand comparison and SimSite3D method of protein site comparison identified candidate ligands with the potential to affect CcO by specifically interacting at the bile acid site. However, neither of these results provided information about the interactions between the candidate ligands and the amino acid side chains of the CcO bile acid site. To understand the binding orientation and relative energetic favorability of candidate molecules, these ligands were docked into the RsCcO bile acid site with SLIDE. The docked ligands interacted with eight residues: P315 and Y318 in subunit I and H96, S98, E101, I102, W104, and T105 in subunit II (Table 2) . Additionally, the diverse protein sites aligned to RsCcO by SimSite3D indicate five residues, based on aligned chemical groups, are responsible for the dominant chemical interactions in the bile acid site. These residues are P315 in subunit I and H96, S98, E101, and T105 in subunit II ( Figure 3 ). The consensus between SLIDE docking and SimSite3D alignment of five amino acids supports the role of these residues in ligand binding and will guide mutagenesis efforts in subsequent work.
In addition to the identification of five consensus residues in the bile acid site, SimSite3D alignment suggests variation in hydrophobic and hydrophilic ligand binding. The SimSite3D protein site classes that bound flavin, nicotinamide, or nucleotide ligands contained chemical groups analogous to the five dominant residues in the bile acid site ( Retinoic acid, fusidic acid, and the ATP analog elicited a biphasic response: activation at low ligand concentration followed by inhibition at higher concentration ( Figure 5B ). This behavior has been observed previously upon addition of amphipathic ligands to the RsCcO mutant, E101A, under standard assay conditions (0.06% LM) and to WT in 0.01% detergent ( Figure 6 ). This initial activation effect in E101A has been attributed to chemical rescue by carboxyl group replacement and the displacement of inhibitory detergent, while the subsequent inhibition is hypothesized to result from a ligand-specific effect. 33 Detergent sensitivity of the larger, more hydrophobic bile acid site in the E101A mutant, but not in the WT, has been demonstrated. 33 Additionally, detergent sensitivity to biphasic ligand-induced effects is only observed in the E101A mutant and not in the WT enzyme. 52 These results suggest that biphasic effects of ligands binding to the WT enzyme are 14 due to more than one interaction mode, activating at low concentrations and inhibiting at high concentrations, independently of detergent. Yet these biphasic effects are associated with the bile acid region since both are altered by the E101A mutation ( Figure 6 and see below). Clearer understanding of this complex activation/inhibition behavior awaits further structural and mutagenic studies.
Mutation and ligand competition analyses support binding to the bile acid site
The three-pronged computational approach was applied to identify biological ligands that may regulate CcO at the bile acid site. To test the binding location of the CcO inhibitors predicted in this work, a form of the RsCcO with a mutation in one of the five consensus bile acid residues (Table 2 and Figure 3 ), E101A, was monitored for ligand-induced activity changes. In addition to E101 being identified as a key residue by both SimSite3D and SLIDE, its mutant form has been shown to be a sensitive system for investigating ligand binding to the bile acid site. 33 When assayed with the E101A mutant, the ATP analog and GDP showed very low stimulation and no inhibition of activity. 52 The cholesterol mimic CHS (IC50 = 530 µM) still inhibited the mutant but with reduced affinity (Figure 6 ). These lower binding affinities are consistent with the predicted dominant role of E101 in hydrophilic ligand binding to the bile acid site (Tables 2 and 3 ). In contrast, both retinoic acid (IC50 = 190 µM) and T3 thyroid hormone (IC50 = 66 µM) appeared to bind more tightly to the mutant, as might be expected based on the predicted lesser dependence of lipidic ligands on E101 (Table 3 ) and the increased overall hydrophobicity of the site. In all cases, the mutation had a significant influence on the ligand behavior, consistent with the predicted characteristics of the bile acid site.
To further test the localization of nucleotide binding to the bile acid site, the ability of the crystallographically-observed DOC ligand to inhibit RsCcO activity was monitored in the presence and absence of the ATP analog. DOC is a stronger inhibitor (IC50 = 1.4 mM) than the ATP analog 15 (IC50 = 4.4 mM) and can lower RsCcO activity by more than 90% (Figure 7) . At 5 mM concentration, the ATP analog alone elicits no effect as this is the mid-point of the ligand's biphasic affect ( Figure 5B ). However, at this concentration, the ATP analog prevented DOC in the 0-2 mM range from inhibiting RsCcO activity, showing its ability to compete with the bile acid ( Figure 7) .
Together, the DOC competition and the effects of the E101A mutation support the prediction that nucleotides bind at the bile acid site and that both their initial activation and subsequent inhibition of CcO is mediated by this region.
Non-saturating cytochrome c concentrations reveal sigmoidal and non-competitive patterns of inhibition
The regulation of mammalian CcO by nucleotides and thyroid hormone has been observed previously by investigating ligand effects at a range of non-saturating to saturating levels of cytochrome c. [25] [26] [27] 50, 51 As the present work has discovered nucleotide effects on bacterial CcO, all Table 4 ). The effects of these ligands were fit with noncompetitive inhibition, selected as its regression better described the activity with non-saturating cytochrome c levels, compared to competitive inhibition models.
Under these assay conditions, RsCcO inhibition by nucleotides gives rise to a sigmoidal curve ( Figure 8B ), similar to the behavior observed in mammalian CcO in the presence of ATP. [25] [26] [27] 50, 51 Originally, this sigmoidal inhibition of bovCcO was argued to represent negative cooperativity between cytochrome c substrate binding sites on the mammalian dimer elicited by ATP binding on the matrix domains of nuclear-encoded subunits IV or VI. 26, 27 Allosteric regulation of bacterial CcO by nucleotides had not been observed prior to this study. This lack of inhibition was suggested to be due to the absence of nuclear-encoded subunits containing the ATP regulatory sites. 53 However, the sigmoidal curves observed in non-saturating cytochrome c assays of RsCcO in the presence of nucleotides suggests that this inhibitory effect must be due to ligand binding on the core subunits of the CcO, potentially at the bile acid site.
DOC inhibition of the RsCcO WT and the E101A mutant ( Figure 9 ) is also consistent with noncompetitive inhibition with respect to cytochrome c, characterized by an altered V max but no change in apparent K m for cytochrome c. Additionally, the T3 thyroid hormone noncompetitively inhibits the RsCcO WT (data not shown). These results suggest that CcO inhibition by ligand binding to the bile acid site, including the sigmoidal inhibition by nucleotides, is unlikely to be explained by allosterically altered cytochrome c affinity. An alternative model consistent with the kinetic, crystallographic 33 and spectral studies 33, [35] [36] [37] is preferential ligand binding to the oxidized form of the enzyme, affecting K-path proton uptake (see Discussion).
Discussion
CcO regulates cell metabolism and oxidative phosphorylation efficiency. [14] [15] [16] Its function is also controlled through highly regulated expression and assembly [14] [15] [16] and tissue specific isoforms. 17 Eukaryotic CcO is subject to phosphorylation of at least fourteen characterized sites, including three sites on the subunit I-III core. 23 In addition, regulation by adenine nucleotides [25] [26] [27] 50, 51, 53 and other small molecules 25, 33, [54] [55] [56] [57] has been reported. The structural and mechanistic basis of these observed regulatory processes is difficult to investigate in the complex mammalian enzyme. However, the simpler bacterial model system has permitted computational, mutagenic, and functional analyses to characterize small molecule regulation at a conserved bile acid binding site.
33,34
Physiological relevance of identified CcO inhibitors
This work's three-pronged computational approach has identified five candidate ligands that affect CcO activity and have previously been tied to metabolic regulation. Thyroid hormones, including T3, have been shown to stimulate metabolism, 58 to interact specifically with intact mitochondria, 54, 59, 60 and to alter CcO activity. 61, 62 Retinoic acid, the degradative product of the essential vitamin A, has been tied to mitochondrial functions including transcriptional regulation, thermogenesis, and apoptosis. 63, 64 High ratios of ATP / ADP, but not other nucleotides 50 , have been shown to inhibit mammalian CcO. 25, 26, 51 Additionally, fusidic acid, a porphyrin-binding mimic, 65 has been identified as a CcO inhibitor. It is important to note that porphyrin molecules are not present in the Binding MOAD database and were therefore not evaluated by ROCS or SimSite3D.
However, protoporphyrin IX and bilirubin have been previously shown to strongly interact with the CcO bile acid site and affect activity. 33 One interpretation of these results is that the conserved bile acid site is a polyspecific regulatory site whose ligands may include ATP, GDP, steroids, retinoic acid, T3 thyroid hormone, and porphyrins. This site may then regulate oxidative phosphorylation based on local energetic demand using a varied set of ligands, whose abundance, affinity and effects will depend on the tissue, the nuclear-encoded subunit isoform and the metabolic state. It is interesting to note that bovCcO subunit VIa impacts directly on the bile acid binding site 30 and could modify the binding site's specificity through subunit phosphorylation. 23, 24 In addition, the location of the bile acid site in bovCcO is at the crystallographic dimer interface and in proximity to a cardiolipin site, raising further possibilities of variable ligand specificity and regulatory influence on supercomplex formation.
48
Ligand binding to the CcO bile acid site may arrest the protein's active site in an oxidized state
Previous work concluded that the nature of the regulatory effect of bile acid site ligands involved inhibition of the K proton uptake path. 33 In the fully active enzyme starting from the oxidized state, transfer of the first two electrons from cytochrome c results in a reduced active site (heme a 3 2 + /Cu B 1+ ) which can then bind oxygen and proceed with catalysis of oxygen reduction. 3, 66 In contrast, inhibition of the K-path favors retention of electrons by heme a and Cu A such that the active site is not reduced and has low affinity for oxygen. 33, [35] [36] [37] This inhibited state is observed spectrally as an increased steady-state ratio of reduced heme a to reduced heme a 3 upon ligand binding to the bile acid site or mutation of K-path residues. 33, 36, 37 The simplest interpretation of these observations is a direct block of K-path-dependent reduction of heme a 3 . If, instead, ligand binding allosterically inhibited the D proton uptake path, irreversible suicide inactivation would be expected. 67, 68 However, this phenomenon is not observed. Therefore, by regulating CcO through the K-path, enzyme activity can be controlled transiently in response to changing physiological conditions without altering the enzyme's integrity.
Two hypotheses have been proposed for the mechanism of K-path inhibition. 33 Firstly, mutations and ligand binding to the bile acid site may disrupt or constrain dynamic water molecules likely required for proton conductance in the K-path. 33, 34, 69 Indeed, the RsCcO crystal structure in the DOC-bound state shows an increased number of well-resolved, stable water molecules in the Kpath entry. 31 Secondly, mutations and ligand binding may restrict conformational change of subunit I helix VIII, 33 which has been shown to be flexible by crystallography, 70 solvent accessibility, 71 and intrinsic flexibility calculations. 72 The latter hypothesis is further supported by crystallographic studies indicating preferential binding of DOC to the oxidized form 33 and the sigmoidal kinetics of nucleotide inhibition ( Figure 8B ), suggesting that at low cytochrome c concentrations (hence more oxidized state) the ligands bind with greater affinity.
A plausible rationale for controlling CcO via affecting the K-path may be understood by considering the conservation of this path and its role in the catalytic cycle. The K-path is the only proton uptake path conserved in heme/copper oxidases from bacteria to mammals. 73, 74 Therefore, the K-path represents both an ancestral and conserved target for regulation. Further, by blocking the K-path, the enzyme is arrested in a semi-oxidized state (Cu A , heme a reduced; Cu B , heme a 3 oxidized), which has a low affinity for O 2 binding, 66, 75, 76 lessening the probability of forming damaging reactive oxygen species. Indeed, a form of bovCcO with slowed turnover, a similar decreased heme a to a 3 electron transfer rate, and an oxidized active site has been previously characterized as the "resting" or "slow" form of CcO. [77] [78] [79] [80] [81] [82] We suggest that this commonly observed state could represent a form in which a detergent, such as cholate, or other ligand is already occupying the bile acid site. A similar hypothesis was previously proposed 82 with respect to another bile acid binding site that is also at the dimer interface of the bovine enzyme, but is not conserved in the bacterial form. However, unlike the bovCcO resting form, [78] [79] [80] [81] [82] The conserved D-and K-paths for proton uptake are represented as dashed lines leading from the internal side of the membrane to the active site. 
